- Home
- BBIO
as 05-09-2025 4:00pm EST
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | PALO ALTO |
| Market Cap: | 6.7B | IPO Year: | 2019 |
| Target Price: | $57.09 | AVG Volume (30 days): | 3.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.54 | EPS Growth: | N/A |
| 52 Week Low/High: | $21.62 - $39.47 | Next Earning Date: | 04-29-2025 |
| Revenue: | $127,415,000 | Revenue Growth: | -41.71% |
| Revenue Growth (this year): | 13.67% | Revenue Growth (next year): | 118.02% |
Stock Insider Trading Activity of BridgeBio Pharma Inc. (BBIO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Lo Andrew | BBIO | Director | May 2 '25 | Sell | $38.50 | 100,000 | $3,849,900.00 | 105,583 | |
| Apuli Maricel | BBIO | Chief Accounting Officer | May 2 '25 | Sell | $38.51 | 1,026 | $39,509.11 | 147,639 | |
| Kumar Neil | BBIO | Chief Executive Officer | Apr 22 '25 | Sell | $34.11 | 75,000 | $2,558,025.00 | 4,873,447 | |
| Ellis Andrea | BBIO | Director | Apr 14 '25 | Sell | $35.00 | 10,000 | $350,000.00 | 12,000 | |
| Ellis Andrea | BBIO | Director | Apr 1 '25 | Sell | $34.05 | 30,000 | $1,021,500.00 | 12,000 | |
| Kumar Neil | BBIO | Chief Executive Officer | Mar 25 '25 | Sell | $36.87 | 75,000 | $2,764,942.50 | 4,873,447 | |
| Valantine Hannah | BBIO | Director | Mar 6 '25 | Sell | $32.58 | 12,875 | $419,499.69 | 1,764 | |
| KKR Genetic Disorder L.P. | BBIO | 10% Owner | Mar 5 '25 | Sell | $32.96 | 6,000,000 | $197,760,000.00 | 19,260,971 | |
| Kumar Neil | BBIO | Chief Executive Officer | Feb 25 '25 | Sell | $33.58 | 75,000 | $2,517,971.14 | 4,873,447 | |
| STEPHENSON BRIAN C | BBIO | CFO and Treasurer | Feb 25 '25 | Sell | $33.68 | 8,500 | $282,114.88 | 102,564 |
Latest BridgeBio Pharma Inc. News
BBIO Breaking Stock News: Dive into BBIO Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025
MT Newswires
3 days ago
Bridgebio Pharma Insider Sold Shares Worth $3,849,900, According to a Recent SEC Filing
MT Newswires
4 days ago
Mizuho Adjusts Price Target on BridgeBio Pharma to $60 From $53, Maintains Outperform Rating
Simply Wall St.
9 days ago
High Growth Tech Stocks In The US Market May 2025
Simply Wall St.
9 days ago
BridgeBio Pharma First Quarter 2025 Earnings: Beats Expectations
Insider Monkey
9 days ago
Why BridgeBio Pharma, Inc. (BBIO) Surged on Wednesday
Investor's Business Daily
9 days ago
BridgeBio Breaks Out After Pfizer-Rivaling Heart Drug Obliterates Sales Expectations
Thomson Reuters StreetEvents
9 days ago
Q1 2025 BridgeBio Pharma Inc Earnings Call
Compare BBIO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BBIO BridgeBio Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.